^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
allitinib (AST1306)
i
Other names: AST1306, ALS-1306, AST 6
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Allist
Drug class:
EGFR inhibitor, HER2 inhibitor
Related drugs:
11ms
Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment. (PubMed, Head Neck)
These findings hold promise for the development of more personalized and effective treatment approaches for HNSCC patients.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MGMT (6-O-methylguanine-DNA methyltransferase) • CCNA1 (Cyclin A1)
|
Erbitux (cetuximab) • Gilotrif (afatinib) • allitinib (AST1306)
over2years
Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. (PubMed, Int J Mol Sci)
Our results indicate that allitinib was more effective than afatinib in NSCLC cell lines. KRAS mutations increased aggressive behavior through upregulation of the focal adhesion-PI3K-Akt-mTOR-signaling in NSCLC cells. Significantly, everolimus restored sensibility and improved cytotoxicity of EGFR inhibitors in the KRAS mutant NSCLC cell lines.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS G12S • MTOR mutation • KRAS overexpression • MTOR overexpression
|
Gilotrif (afatinib) • everolimus • allitinib (AST1306)
over2years
A real world study on the relationship between drug resistance of targeted therapy and prognosis of HER-2-positive advanced breast cancer (PubMed, Zhonghua Zhong Liu Za Zhi)
Among them, targeted drugs for HER-2 included trastuzumab, pertuzumab, T-DM1, RC48-ADC, lapatinib, pyrotinib, allitinib, sipatinib, seratinib. The median overall survival time of the two groups was 24.9 months and 40.4 months, respectively, with statistical significance (P<0.001). Primary resistance to HER-2 is one of the factors of poor prognosis in HER-2 positive breast cancer, and its mechanism needs to be further explored.
Journal • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive
|
lapatinib • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Irene (pyrotinib) • Aidixi (disitamab vedotin) • allitinib (AST1306)
almost4years
To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer (clinicaltrials.gov)
P2, N=36, Not yet recruiting, Chinese Academy of Medical Sciences
Clinical • New P2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Focus V (anlotinib) • allitinib (AST1306)
Share via
